title: Curative effect of Xuebijing injection on severe pulmonary contusion.
abstract: OBJECTIVE
  To investigate the curative effects of Xuebijing (XBJ) injection, a Chinese patent medicine, on severe pulmonary contusion (PC).
  
  
  METHODS
  Sixty-three patients with PC were randomized to conventional therapy plus XBJ injection (n = 33) or conventional therapy alone (n = 30). Between groups differences in corticosteroid treatment, immune regulation therapy, hemofiltration, infusion volume, transfusion volume and antibiotic period were measured, as were intensive care unit (ICU)-free time, ventilation time, 28-day mortality rate and incidence of ventilation-associated pneumonia (VAP). Serum concentrations of procalcitonin (PCT), tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, and IL-10, white blood cell (WBC) counts and percentages of human leukocyte antigen DR/ CD14+ (HLA-DR/CD14+) peripheral blood mononuclear cells were compared. Markers of ventilation were determined by blood gas analysis and ventilator parameters.
  
  
  RESULTS
  WBC counts and serum concentrations of PCT, TNF-alpha, IL-6 and IL-10 were reduced significantly more quickly, and CD14+ percentage was increased significantly earlier, in the XBJ group than in the control group (P < 0.05 each).The level of ventilation and oxygenation index were ameliorated earlier in the XBJ than in the control group (P < 0.05). XBJ treatment significantly reduced ICU-free time, ventilation time and incidence of VAP (P < 0.05 each), but had no effect on 28-day mortality rate
  
  
  CONCLUSIONS
  XBJ treatment can shorten ICU-free and ventilation times and reduce the incidence of VAP, improving outcomes in patients with severe PC. XBJ may act by regulating inflammation and immunity, alleviating systemic inflammatory response syndrome induced by trauma.
authors.forename: Yi
authors.initials: Y
authors.lastname: Chen
authors.forename: Huasheng
authors.initials: H
authors.lastname: Tong
authors.forename: Wang
authors.initials: W
authors.lastname: Zhang
authors.forename: Xingqin
authors.initials: X
authors.lastname: Zhang
authors.forename: Zhigguo
authors.initials: Z
authors.lastname: Pan
authors.forename: Junming
authors.initials: J
authors.lastname: Qiu
authors.forename: Ruihuan
authors.initials: R
authors.lastname: Pan
authors.forename: Lei
authors.initials: L
authors.lastname: Su
mesh_terms: D000293:Adolescent; D000328:Adult; D003288:Contusions / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008171:Lung Diseases / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D055815:Young Adult
chemical_list: D004365:Drugs, Chinese Herbal; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; C549376:Xuebijing; D016753:Interleukin-10